Review paper

Towards personalized treatment for early stage HER2-positive breast cancer

Volume: 17, Issue: 4, Pages: 233 - 250
Published: Dec 13, 2019
Abstract
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized disease has been chemotherapy and 1 year of adjuvant HER2-targeted therapy, typically with the anti-HER2 antibody trastuzumab. Despite the effectiveness of this treatment, disease relapse occurs in a subset of patients; thus, focus has been placed on escalating treatment by either combining...
Paper Details
Title
Towards personalized treatment for early stage HER2-positive breast cancer
Published Date
Dec 13, 2019
Volume
17
Issue
4
Pages
233 - 250
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.